Fungal test could save people from fatal infection
A new test which creators say could one day save the lives of people suffering from a deadly fungal infection is being developed at the University of Exeter.
Mucormycosis, commonly known as black fungus disease, spiked during the second wave of the Covid-19 pandemic.
Now, Professor Chris Thornton, a professor in fungal immunology at the university, has developed a prototype lateral flow test, which could save valuable time in getting patients the treatment they need.
The test has been validated using patient samples could be ready to use in hospitals within three years if it passes regulatory checks, project leaders said.
More news stories for Devon
Listen to the latest news for Devon
The fugal spores that cause black fungus disease are ever-present in the environment and harmless for most people. The disease is rare and thought to only affect those with compromised immunity.
However, a combination of Covid infection, poorly-managed diabetes and an over-use of steroids to control lung inflammation from Covid led to a spike in infections.
In 2021, there was an epidemic in India, with 40,000 cases leading to 3,500 deaths. Many of the survivors were left with facial disfigurements.
Although still at prototype stage, a new study published in the Journal of Clinical Microbiology has shown the new test to be swift and accurate in identifying the disease.
Professor Thornton, co-author of the study, said: "Mucormycosis is an horrific disease, which spreads rapidly in the body and can leave people horribly facially disfigured, and is often fatal."
"Early diagnosis is crucial for the best outcome. This study shows that our new test is quick and effective.
"These exciting results are a critical milestone in the development and validation of the test, which we aim to commercialise in the next three years."
The study was conducted in partnership with colleagues at Besançon University hospital in France.
Researchers tested the device in patients with mucormycosis, patients with other fungal infections, and patients without fungal infections.
The test detects mucormycosis in 30 minutes with a high level of specificity and sensitivity.
Follow BBC Devon on X, Facebook and Instagram. Send your story ideas to spotlight@bbc.co.uk.
The deadly 'black fungus' maiming Covid patients
India reports nearly 9,000 'black fungus' cases
Why has India got so many 'black fungus' cases?
University of Exeter
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
2 hours ago
- Medscape
NICE Backs Leadless Pacemakers for Some Heart Patients
The National Institute for Health and Care Excellence (NICE) has provisionally recommended leadless cardiac pacemaker implantation for patients with bradyarrhythmias who require single-chamber pacing. In draft guidance, NICE said there was insufficient evidence to support their use for dual-chamber pacing outside of research settings. Benefits Over Traditional Pacemakers The recommendation is based on an evidence review involving over one million patients across multiple studies. These included a randomised controlled trial, four systematic reviews with meta-analyses, five registry studies, four prospective studies, and two retrospective studies. Leadless pacemakers were found to be effective at detecting abnormal heart rhythms, restoring normal pacing, and improving quality of life. Unlike conventional transvenous pacemakers (TVPs), they do not require a chest incision, reducing the risk of infection and other complications, the regulator noted. 'The evidence demonstrates that leadless pacemakers can effectively regulate heart rhythm while reducing the risk of complications associated with traditional pacemakers, particularly infections and lead-related issues,' said Dr Anastasia Chalkidou, HealthTech programme director at NICE. How Leadless Pacemakers Work Bradyarrhythmias, which affect around 1 in 1000 people are typically treated with TVPs. These devices consist of a subcutaneous pacemaker box and leads that connect to the heart. For single-chamber leadless pacemakers, the proximal end is attached to a deflectable delivery catheter system. It is usually inserted percutaneously through the femoral or jugular vein using an introducer sheath. It is then moved into the right atrium, through the tricuspid valve, and into the right ventricle. Dual-chamber systems, which are still under evaluation, involve placing two devices — one in the right atrium and another in the right ventricle — during a single procedure. NICE highlighted that TVPs are known to carry risks, including lead failure and generator-related complications. Leadless pacemaker implantation may be preferable for patients with a history of device infection, endocarditis, immunosuppression, limited vascular access, or high infection risk. Call for Further Research While the draft guidance supports leadless pacemakers for single-chamber pacing, NICE said that more evidence is needed before endorsing their wider use. This includes research on patient selection — such as age, comorbidities, and the underlying cause of bradyarrhythmia — as well as data on implantation sites and clinical outcomes. Long-term durability of leadless devices also remains an area for investigation. 'The incidence of bradyarrhythmias increases with age, making this guidance particularly relevant to our ageing population,' said Professor Tom Clutton-Brock, chair of NICE's interventional procedures advisory committee. The draft guidance is open for public consultation until 23 July 2025. The advisory committee will meet again on 11 September 2025 to review feedback and finalise recommendations.
Bloomberg
3 hours ago
- Bloomberg
Cyberattack on UK Health Firm Contributed to Patient Death
A cyberattack that caused disruption at hospitals in London last year contributed to the death of a patient, health officials have confirmed for the first time. The incident occurred after a Russian hacking gang in June 2024 targeted Synnovis, a contractor that provides blood testing, transfusion and other pathology services to the UK's National Health Service, or NHS. The breach triggered a major crisis at health-care providers predominantly in the southeast of the city.
Gizmodo
4 hours ago
- Gizmodo
Good News! Caffeine Might Help Your Cells Live Longer
As if we needed any other reason to drink coffee or tea, new research provides insight into how caffeine supports health and longevity. Researchers in London studying fission yeast—a single-celled organism similar to human cells—have revealed that caffeine impacts aging via an ancient cellular energy system. Their study, published yesterday in the journal Microbial Cell, bolsters previous research suggesting that caffeine reduces the risk of age-related diseases and carries important implications for future longevity research. Plus, it gives you a good comeback next time your partner tells you you're drinking too much coffee. While most people think of caffeine within the context of coffee or tea, it is a naturally occurring central nervous system stimulant found in coffee beans, tea leaves, cocoa beans, kola nuts, and more. Perhaps unsurprisingly, caffeine is the most widely used psychoactive stimulant in the world. While the energy boost our cup of Joe delivers each morning is enough for most of us to justify its daily consumption, caffeine has also been associated with a number of health benefits, such as depression relief, longer lifespan, and a lower risk of cardiovascular disease and type 2 diabetes. The team had previously discovered that caffeine promotes lengthier cell lives by influencing TOR (Target of Rapamycin)—a biological switch that instructs cells when to grow given the availability of food and energy. More broadly, the growth regulator manages the energy and stress responses of living things. In the new study, however, the team found that caffeine actually impacts TOR indirectly by activating a system called AMPK, essentially a sort of cellular fuel gauge, as described by a Queen Mary University of London statement. 'When your cells are low on energy, AMPK kicks in to help them cope,' Charalampos Rallis, senior author of the study and a researcher at Queen Mary University of London's Research Centre of Molecular Cell Biology, said in the statement. 'And our results show that caffeine helps flip that switch.' Rallis and his colleagues used the yeast model to demonstrate that caffeine's influence on AMPK positively affects functions related to aging and disease, such as cell growth, DNA repair, and stress response. 'These findings help explain why caffeine might be beneficial for health and longevity,' said John-Patrick Alao, lead author of the study and a biochemist at the University of East London. 'And they open up exciting possibilities for future research into how we might trigger these effects more directly—with diet, lifestyle, or new medicines.' Coffee and tea lovers, rejoice!
